Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


IQur wins 2005 DOH award for healthcare innovation, closes financing
and announces deal on anti-fibrosis therapeutics

Southampton, UK, 9th November 2005 ... Advances announced today by the UK-based Company iQur, reinforce its position as a world leader in the development of new treatments for liver disease. It has been chosen as the 2005 winner of the Medical Futures Department of Health Award for Best National Healthcare Innovation for its Hepatitis C genotyping service, that can revolutionise the cost effectiveness of treatment for Hepatitis C. Previously trading as HepCgen, iQur also announced today the final close of an oversubscribed £2.6 million follow-on financing, as well as the signing of a major licensing deal with the University of Southampton for its patent estate in the treatment of liver fibrosis.

Commenting on these significant announcements, Paul Colford, CEO, said: 'I am delighted that iQur's ground breaking research into the diagnosis, treatment and monitoring of major liver diseases has been recognised on such a wide range of fronts, by the Department of Health, the investment community and the University, and underlines our company's goal to become THE liver disease company.'

Referred to as the 'Oscars of Healthcare', the Medical Futures Innovations Awards are the most prestigious in the industry. iQur was presented with the Department of Health Award for Best National Health Innovation 2005 for its research into the detection, treatment and monitoring of Hepatitis C and other liver diseases at the Awards ceremony in London by supermodel Caprice.

Accepting the Award, Professor William Rosenberg, iQur's founding CSO said: 'This award is testament to the importance and success of our diagnostic services. iQur is the first Southampton based company to be recognised at this level and we achieved this as a result of our expert team and their tremendous dedication to develop better care for the increasing threat of Hepatitis C across the globe. iQur's strategies enable therapies to be tailored to the individual patient - potentially reducing treatment time and side effects, saving the NHS millions of pounds in clinical and pharmaceutical expenses. Following this innovation will be our simple blood test to reduce the requirement of serial liver biopsy across Europe, then the introduction of better treatment for HCV.'

As well as recognition within the medical community, iQur has also attracted positive attention from the investment community, and has successfully raised further investment of £2.6 million in an oversubscribed funding round. The funding will be used to establish the company's Diagnostic Services business, the iQur® Speciality Pharmaceutical distribution division and grow various therapeutic in-licensing agreements.

Commenting on the investment and Award, Board Director, David Norwood and CEO of IP2IPO, a major investor in iQur said: 'UK universities are originators of some of the best novel intellectual property in the world, and the University of Southampton and the progress of the iQur team to deliver innovation to the global problem of liver disease, specifically, Hepatitis C, is an inspiration to all our portfolio companies, and fully reflective of our mission. iQur's progress is underlined by the success of this financing round.'

In addition, the Company has also extended its focus and pipeline beyond Hepatitis C into liver fibrosis and secured a licensing deal with The University of Southampton. Liver fibrosis is the result of fatty liver disease, obesity, hepatitis, alcoholic liver disease and others. Over the last 20 years, the University has achieved an international reputation for its study of the pathology of fibrosis, cirrhosis, then cancer of the liver.

Colford adds: ' We have seen some compelling evidence that the progress of fibrosis can be halted, and perhaps even reversed, with the intellectual property we have licensed. In the best case, we can arrest the progression of liver disease regardless of its cause. More conservatively, we hope to introduce a liver protect

Publisher Contact Information:

iQur Ltd. (formerly HepCgen)
+ 44 (0)2380 798945

Company profile of iQur Ltd. (formerly HepCgen)
Past press releases of iQur Ltd. (formerly HepCgen).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 6€9.3MSoftware development
Dec 6€1.5MConsumer applications
Dec 6€3.7MInternet commerce
Dec 5€8.0MNanotechnology
Dec 5€11.0MBiotechnology
Dec 5€11.0MRobotics
Dec 5N/ARobotics

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.